Trial Profile
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms 17-214-08; PIVOT IO 001
- Sponsors Bristol-Myers Squibb
- 11 Oct 2023 Status changed from active, no longer recruiting to completed.
- 31 Aug 2023 Results for safety and efficacy of Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma, published in the Journal of Clinical Oncology
- 21 Jul 2023 This trial has been completed in France, according to European Clinical Trials Database record.